Iradimed Corporation (NASDAQ: IRMD) surged 4.45% on Friday, outperforming the S&P 500’s modest 0.3% gain, following a strong quarterly earnings report. The company reported a 13% revenue increase to nearly $22 million, exceeding analyst expectations of $20.8 million. Net income rose 24% to over $5.8 million, with adjusted earnings per share of $0.49 beating the forecast of $0.46.
The primary driver of Iradimed’s growth was its MRI-compatible intravenous infusion pump devices, which generated nearly $15.4 million in revenue—a 19% increase. The company also highlighted positive early reception for its newly launched IV pump system, the 3870, signaling potential for continued growth. Management reaffirmed its revenue guidance of $91 million to $96 million and projected adjusted earnings per share between $2.06 and $2.21.
For market professionals, Iradimed’s strong performance and positive outlook in the aging healthcare sector underscore its potential as a solid investment in the niche medical device market.
Source: fool.com